TMDX Relative Valuation
TMDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TMDX is overvalued; if below, it's undervalued.
Historical Valuation
Transmedics Group Inc (TMDX) is now in the Fair zone, suggesting that its current forward PS ratio of 6.24 is considered Fairly compared with the five-year average of -14.17. The fair price of Transmedics Group Inc (TMDX) is between 83.58 to 251.61 according to relative valuation methord.
Relative Value
Fair Zone
83.58-251.61
Current Price：109.88
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
13.96
P/B
Median3y
16.74
Median5y
13.25
-1.70
FCF Yield
Median3y
-3.95
Median5y
-4.51
Competitors Valuation Multiple
The average P/S ratio for TMDX's competitors is 3.12, providing a benchmark for relative valuation. Transmedics Group Inc Corp (TMDX) exhibits a P/S ratio of 6.09, which is 95.07% above the industry average. Given its robust revenue growth of 48.21%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Transmedics Group Inc (TMDX) currently overvalued or undervalued?
What is Transmedics Group Inc (TMDX) fair value?
How does TMDX's valuation metrics compare to the industry average?
What is the current P/B ratio for Transmedics Group Inc (TMDX) as of Jul 20 2025?
What is the current FCF Yield for Transmedics Group Inc (TMDX) as of Jul 20 2025?
What is the current Forward P/E ratio for Transmedics Group Inc (TMDX) as of Jul 20 2025?